Endothelial growth factor receptor inhibitors in recurrent metastatic cancer of the head and neck

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Head and Neck

• Publication date

  2016-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hed.24083PMID 25900280
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The SPECTRUM of findings in treatment options for recurrent/metastatic head and neck cancer.

  2013cited by this paper
• Progression-free survival (PFS) as a measure of efficacy for anti-EGFR antibodies in recurrent/metastatic (R/M) squamous cell carcinoma of head and neck (SCCHN).

  2013cited by this paper
• Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.

  2013cited by this paper
• Cancer statistics, 2012

  2012cited by this paper
• A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  2012influential reference
• DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN).

  2012influential reference
• Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.

  2011cited by this paper
• Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial.

  2011influential reference
• American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

  2011cited by this paper
• Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy

  2011cited by this paper
• Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer.

  2010cited by this paper
• Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

  2010cited by this paper
• Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).

  2010cited by this paper
• Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab

  2010cited by this paper
• BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study.

  2010cited by this paper
• A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A trial of the Eastern Cooperative Oncology Group (ECOG).

  2009cited by this paper
• Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

  2009cited by this paper
• Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

  2009cited by this paper
• BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors.

  2008cited by this paper
• Platinum-based chemotherapy plus cetuximab in head and neck cancer.

  2008cited by this paper
• Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.

  2007cited by this paper
• A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors

  2007cited by this paper
• Epidermal growth factor receptor targeting in cancer.

  2006cited by this paper
• Epidermal growth factor receptor biology in head and neck cancer.

  2006influential reference
• Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.

  2005cited by this paper
• Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.

  2005cited by this paper
• A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy.

  2005cited by this paper
• Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.

  2005cited by this paper
• Specificity within the EGF family/ErbB receptor family signaling network

  1998cited by this paper
• Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis.

  1994influential reference
• Immunohistochemical study of glutathione‐related enzymes and proliferative antigens in lung cancer. Relation to cisplatin sensitivity

  1993cited by this paper
• Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.

  1992cited by this paper
• Gene amplification and overexpression of epidermal growth factor receptor in squamous cell carcinoma of the head and neck

  1992influential reference
• A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.

  1992cited by this paper
• Cancer statistics

  1989cited by this paper
• Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity.

  1984cited by this paper

• Novel genetic alterations and their impact on target therapy response in head and neck squamous cell carcinoma

  2019cites this paper
• EGF induces epithelial-mesenchymal transition and cancer stem-like cell properties in human oral cancer cells via promoting Warburg effect

  2016cites this paper